Literature DB >> 30145777

Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies.

Bertrand Covin1, Mathieu Roumiguié1, Marie-Laure Quintyn-Ranty2, Pierre Graff3, Jonathan Khalifa3, Richard Aziza4, Guillaume Ploussard1, Daniel Portalez4, Bernard Malavaud5.   

Abstract

PURPOSE: To evaluate image-guided Transperineal Elastic-Registration biopsy (TPER-B) in the risk-stratification of low-intermediate risk prostate cancer detected by Transrectal-ultrasound biopsy (TRUS-B) when estimates of cancer grade and volume discorded with multiparametric Magnetic Resonance Imaging (MRI).
METHODS: All patients referred for active surveillance or organ-conservative management were collegially reviewed for consistency between TRUS-B results and MRI. Image-guided TPER-B of the index target (IT) defined as the largest Prostate Imaging-Reporting Data System-v2 ≥ 3 abnormality was organized for discordant cases. Pathology reported Gleason grade, maximum cancer core length (MCCL) and total CCL (TCCL).
RESULTS: Of 237 prostate cancer patients (1-4/2018), 30 were required TPER-B for risk-stratification. Eight cores were obtained [Median and IQR: 8 (6-9)] including six (IQR: 4-6) in the IT. TPER-B of the IT yielded longer MCCL [Mean and (95%CI): 6.9 (5.0-8.8) vs. 2.6 mm (1.9-3.3), p < 0.0001] and TCCL [19.7 (11.6-27.8) vs. 3.6 mm (2.6-4.5), p = 0.0002] than TRUS-B of the gland. On TPER-B cores, longer MCCL [Mean and (95%CI): 8.7 mm (6.7-10.7) vs. 4.1 mm (0.6-7.6), p = 0.002] were measured in Gleason score-7 cancers. TPER-B cores upgraded 13/30 (43.3%) patients. 14/30 (46.7%) met University College London-definition 1 and 18/30 (60.0%) definition 2, which correlate with clinically significant cancers > 0.5 mL and > 0.2 mL, respectively. 7/16 (43.8%) patients under active surveillance were re-allocated toward prostatectomy (n = 5) or radiation therapy (n = 2). In 14 patients not yet assigned, TPER-B risk-stratification spurred the selection (13/14, 92.9%) of treatments with curative intent.
CONCLUSION: Image-guided TPER-B of the index target provided more cancer material for pathology. Subsequent re-evaluation of cancer volume and grade switched a majority of patients towards higher-risk groups and treatments with curative intent.

Entities:  

Keywords:  Biopsy; Diagnostic imaging; Endoscopy; Prostatic Neoplasms

Mesh:

Year:  2018        PMID: 30145777     DOI: 10.1007/s00345-018-2459-4

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  5 in total

1.  MRI-targeted biopsies: What's next?

Authors:  Guillaume Ploussard; Alberto Briganti
Journal:  World J Urol       Date:  2019-02       Impact factor: 4.226

Review 2.  The current role of MRI for guiding active surveillance in prostate cancer.

Authors:  Guillaume Ploussard; Olivier Rouvière; Morgan Rouprêt; Roderick van den Bergh; Raphaële Renard-Penna
Journal:  Nat Rev Urol       Date:  2022-04-07       Impact factor: 16.430

3.  Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies.

Authors:  Mathieu Roumiguié; Guillaume Ploussard; Léonor Nogueira; Eric Bruguière; Olivier Meyrignac; Marine Lesourd; Sarah Péricart; Bernard Malavaud
Journal:  Cancers (Basel)       Date:  2020-01-24       Impact factor: 6.639

4.  MRI Characteristics Accurately Predict Biochemical Recurrence after Radical Prostatectomy.

Authors:  Cécile Manceau; Jean-Baptiste Beauval; Marine Lesourd; Christophe Almeras; Richard Aziza; Jean-Romain Gautier; Guillaume Loison; Ambroise Salin; Christophe Tollon; Michel Soulié; Bernard Malavaud; Mathieu Roumiguié; Guillaume Ploussard
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

5.  Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading Prediction.

Authors:  Guillaume Ploussard; Jean-Baptiste Beauval; Raphaële Renard-Penna; Marine Lesourd; Cécile Manceau; Christophe Almeras; Jean-Romain Gautier; Guillaume Loison; Daniel Portalez; Ambroise Salin; Michel Soulié; Christophe Tollon; Bernard Malavaud; Mathieu Roumiguié
Journal:  J Clin Med       Date:  2020-01-15       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.